Reversible Cryopreservation Continues to be the Point of Focus to Expand Cryonics – Fight Aging!
The cryonics industry has long been a non-profit, small field, with only a few hundred individuals having undergone cryopreservation upon death. The potential for a restored life in a technologically advanced future exists for these cryopreserved individuals, provided their brain structure is sufficiently preserved. However, research and resources in the cryonics field are limited, hindering the advancement of technology and protocols for better preservation.
Efforts to expand the cryonics industry face challenges, requiring a focus on developing robust, reversible cryopreservation techniques for tissues and organs to increase funding and commercial development. Despite these challenges, progress is being made with well-funded initiatives like Laura Deming’s work on reversible cryopreservation.
A recent standout in the field is the startup Cradle, which has received $48 million in funding to develop whole-body reversible cryopreservation technology. By pausing molecular motion through cooling, Cradle aims to prevent tissue damage and potentially revolutionize fields like organ transplantation and neuroscience research. The company has achieved significant milestones, showcasing the potential for whole-body reversible cryopreservation to become a reality.
